Central Nervous System Therapeutic Market

The global cancer nervous system therapeutic market was more than US$100 Bn in 2020. Fairfield Market Research envisions a promising growth outlook for the market in the upcoming years.

Market Analysis in Brief

The global cancer nervous system therapeutic market is anticipated to attain unprecedented growth levels, primarily driven by the growing prevalence of central nervous system (CNS) disorders such as Alzheimer’s disease. As the global population ages and individual lifestyle changes, the burden of these disorders is anticipated to rise, leading to the rapid expansion of the central nervous system therapeutic market. Over recent years, advances in neuroscience research, drug discovery, and medical technologies have led to the development of innovative therapies. Such technological developments are further accelerating the growth trajectory of the market. In this favourable business landscape, prominent industry participants are engaging in strategic partnerships and product innovations to gain a competitive edge. Gauging the momentum of these trends, the global market is poised to reach unprecedented levels of growth.

Key Report Findings

• The growing prevalence of CNS diseases, rapid technological advancements, and the rise in the geriatric population are likely to propel the market growth trajectory
• With rising investments in novel therapies for the central nervous system therapeutic market, North America is anticipated to hold a dominant share of the global market
• Biogen Inc, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Merck & Co., AstraZeneca, and Takeda Pharmaceutical Company Limited, are the key market entities defining the market growth
• Neurovascular Disease, Mental Health Diseases, and CNS Cancer Market are the leading market segments, based on the disease
• In 2020, the central nervous system therapeutic market was valued at more than US$100 Bn

Growth Drivers

Growing Geriatric Population, and Associated Neurological Disorders

The rising geriatric population coupled with associated neurological disorders is positively impacting the global central nervous system therapeutic market. Elder individuals are more susceptible to numerous neurological conditions such as Parkinson’s disease, Alzheimer’s disease, stroke, and dementia CNS therapeutics encompasses a broad range of pharmaceuticals, therapies, and medical devices that target neurological disorders affecting the central nervous system. Therefore, the confluence of the elder population and associated neurological disorders bolsters product demand.

Promising Pipeline Drugs 

The launch of promising products for treating neurological disorders is projected to propagate strong growth waves across the central nervous system therapeutic market. The development of novel drug classes and treatment modalities is likely to offer a broad range of options for CNS disorders and increase access to treatment across developing countries.  This in turn will present diverse treatment options for patients and make therapies more effective and personalised.

Overview of Key Segments

Neurovascular Disease, Mental Health Diseases, and CNS Cancer Market Rise as Crucial Disease Segment

The global central nervous system therapeutic market covers numerous diseases including neurovascular disease, mental health, and CNS cancer. The neurodegenerative diseases segment has been dominating the market for the past few years. The growing incidence of neurodegenerative diseases such as Parkinson’s disease is fuelling the segment’s growth. Another key factor accelerating the segment’s growth is the well-built pipeline of therapeutics for the treatment of various neurodegenerative diseases including Parkinson’s disease.

Closely following, the mental health segment has emerged as the second leading segment in the global central nervous system therapeutic market. The growing prevalence of epilepsy, psychotic disorders, and anxiety disorders is mainly credited to the segment’s rapid expansion. Apart from this, increased awareness about mental health and the easy availability of drugs are also acting as key growth catalysts for the segment.

That said, the CNS cancer segment is predicted to be the most opportunistic segment. An alarming rise in CNS cancer, and subsequently growing demand for its therapeutics is creating business opportunities for the segment’s growth. Furthermore, the high mortality rates have led to increased investments in the research and development of CNS cancer treatment therapeutics.

Growth Challenges

Stringent Regulatory Framework, and Time-consuming Approval Processes

Compared to other therapeutic disease areas, the central nervous system therapeutic research and development require a higher amount of investment. Moreover, due to the blood-brain barrier, the development and approval process gets stretched. The stringent regulatory framework owing to such therapeutics further makes the process more complex. In addition to this, there exist significant challenges in patient recruitment and higher cost per approval for the entire pharmaceutical industry. Moreover, the potential adverse consequence of these drugs is another major growth restraint for the global central nervous system therapeutic market.

Regional Segment

North America Maintains Dominance

North America is set to achieve new growth opportunities in the global central nervous system therapeutic market. The strong presence of prominent market players and intensified efforts to develop novel therapies are primarily driving regional market growth. Furthermore, the growing mental health incidence and neurodegenerative disorders such as multiple cases of sclerosis, Parkinson’s diseases, and Alzheimer’s, are furthering the demand for the central nervous system in the region.

Additionally, the growing awareness campaigns about the diagnosis and treatment of CNS diseases treatment by pharmaceutical firms are increasing the treatment rate in the region, bolstering demand for central nervous system therapeutic. On the other hand, the global central nervous system therapeutic market is anticipated to expand at the highest rate over the forecast period. The improved healthcare infrastructure coupled with a large patient base is creating revolutionary revenue opportunities for the regional market.

Promising Market Entities

Some of the major industry participants in the central nervous system therapeutic market include Biogen Inc, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Merck & Co., AstraZeneca, Takeda Pharmaceutical Company Limited, Novartis AG, and Teva Pharmaceutical Industries Ltd, Johnson & Johnson Private Limited, Pfizer Inc., and GlaxoSmithKline PLC.

Regional Classification of the Global Central Nervous System Therapeutic Market is Described Below:

North America

• U.S.
• Canada

Europe

• Germany
• France
• Spain
• U.K.
• Italy
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East and Africa

• GCC
• South Africa
• Rest of Middle East and Africa